Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14727515 | 1.00 | SLC29A1 (0.51) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL20215742 | 1.00 | SLC29A1 (0.51) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL19981006 | 1.00 | SLC29A1 (0.51) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL17853313 | 0.94 | PRMT5 (0.44) | SLC29A1MEN1KMT2AADORA3 | |
| SCHEMBL15892160 | 0.94 | PRMT5 (0.44) | SLC29A1MEN1KMT2AADORA3 | |
| SCHEMBL23720445 | 0.87 | SLC29A1 (0.49) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL26631287 | 0.84 | SLC29A1 (0.50) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL26631283 | 0.84 | SLC29A1 (0.50) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL30540707 | 0.83 | SLC29A1 (0.48) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL30603353 | 0.82 | TYMP (0.52) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988415-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2018-06-05 | — | — | US | disclosed |
| EP-2749565-B1 | NUCLEOSIDE PHOSPHORAMIDATES FOR PRODUCING NUCLEIC ACIDS | BONAC CORP (JP) | 2017-05-31 | — | — | EP | disclosed |
| EP-3098230-A1 | THIOETHER COMPOUND FOR THE PROTECTION OF THE 2'-HYDROXY GROUP IN NUCLEOSIDES TO BE USED IN OLIGONUCLEOTIDE SYNTHESIS. | Bonac Corporation (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9481702-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2016-11-01 | — | — | US | disclosed |
| US-20160176810-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | BONAC CORPORATION (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176810-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | BONAC CORPORATION (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | BONAC CORPORATION (JP) | 2014-07-24 | — | — | US | disclosed |
| EP-2749565-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | Bonac Corporation (JP) | 2014-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176810-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | DDOST, TENT4A, TRDMT1 | SLC29A1 1104/4885MEN1 2279/4885KMT2A 1607/4885 |
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | DDOST, TENT4A, TRDMT1 | SLC29A1 1104/4885MEN1 2279/4885KMT2A 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.